Visual Acuity Geographic Atrophy Macular Degeneration
Conditions
Interventions
investigational material(s)
Generic name etc : CNTO 2476 (6.0 x 10^4 cells) - Experimental
INN of investigational material :
Therapeutic category code : --- Other
Dosage and Administration for Invest
Sponsors
Janssen Pharmaceutical K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Participant is a suitable candidate for ophthalmologic surgery, is willing and able to comply with the surgical procedure, scheduled visits, treatment plan, laboratory tests and other study procedures. Participant has met criteria of the surgery center anti coagulation protocol, if applicable - Confirmed diagnosis of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) confirmed within 28 days prior to initial randomization by the central reading center using fundus photographs and including the following; a) The study eyes must have at least 1 GA lesion that involves the fovea, and a Macular Photocoagulation Study (MPS) disc areas (DA) of >= 1 and = 0.5 DA, b) GA must be able to be photographed in its entirety and may be contiguous with peripapillary atrophy, c) Retinal photographs, fundus autofluorescence images, and angiography of sufficient quality, allowing assessment of the macular area according to standard clinical practice, can be obtained d) The imaging center must be able to delineate and confirm peripapillary atrophy with fundus photography and fundus autofluorescence, e) Images must include the central field 1, 2, and 3 field images as defined by the University of Wisconsin standards as well as a supero temporal image to capture the subretinal injection area if possible - Female participants must be postmenopausal with last menses 12 months prior, or longer without medical reasons (example, treatment with a drug), or a measured follicle stimulating hormone >= 26 milliinternational units per milliliter (mIU/mL) - Study eyes will have a best corrected visual acuity (BCVA) of 20/80 to 20/800 (Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR value 0.6-1.6). BCVA in the study eye must be worse than the BCVA in the fellow eye at screening - Male participants must be sterile or willing to use 2 approved methods of contraception from first day postoperatively to 3 months postoperatively
Exclusion criteria
Exclusion criteria: - Participant has a history of neovascular ("wet") AMD in the study eye, including any evidence of retinal pigment epithelium rips or evidence of subretinal or choroidal neovascularization. History or evidence of neovascular AMD in the fellow eye is allowed, if antivascular endothelial growth factor (VEGF) therapy has not been required for at least 8 weeks prior to screening - A diagnosis of glaucoma with an intraocular pressure (IOP) >= 25 millimeter of mercury (mm Hg) while being treated with an ocular hypotensive drug. Treatment should be no more than 1 drug preparation/combination, which can contain 1 or 2 ocular hypotensive active ingredients; participants receiving more than 2 ocular hypotensive active ingredients are excluded - Nuclear sclerotic cataract, cortical spoking, posterior subcapsular cataract above Grade 2 per Age Related Eye Disease Study (AREDS) scale or any other ophthalmologic condition that reduces the clarity of the media that, in the opinion of the investigator or reading center, interferes with ophthalmologic examination (example, corneal abnormalities, inadequate pupillary dilation) - Myopia >-8 diopters and participants with >4 diopters of astigmatism, and >+10 diopters of hyperopia - Previous vitrectomy, retinal detachment repair, submacular surgery, other surgical interventions targeting AMD, scleral buckling or glaucoma filtration surgery or any other extraocular or orbital procedure in the study eye that, in the opinion of the surgeon, would hamper the suprachoroidal cannulation procedure in the study eye
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants Showing Improvement From Baseline of Greater Than or Equal to (>=) 15 Letters in Best Corrected Visual Acuity (BCVA) at Month 6 Month 6 | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of Participants Showing Improvement >=15 BCVA Letters From Baseline at 12 Month Percentage of Participants Losing >=15 Best Corrected Visual Acuity (BCVA) Letters From Baseline at 6 and 12 Months Change in Mean Number of BCVA Letters From Baseline at 6 and 12 Months Change in Growth Rate of Geographic Atrophy (GA) Lesion Documented at Baseline to 6 and 12 Months Mean Change in Reading Acuity (RA) From baseline to 6 and 12 Months Mean Change in Maximum Reading Speed (MRS) From Baseline to 6 and 12 Months Mean Change in Critical Print Size (CPS) From Baseline to 6 and 12 Months Mean Change in Low Luminance Best Corrected Visual Acuity (LL BCVA) Letters From Baseline to 6 and 12 Months Percentage of Participants With Gain of >= 15 Letters in LL BCVA From Baseline to 6 and 12 Months Mean Change in Contrast Sensitivity From Baseline to 6 and 12 Months Number of Participants With Significant Changes in Retinal Morphology Percentage of Participants who Convert to Neovascular Age-Related Macular Degeneration (AMD) in the Study Eye and in the Fellow Eye Percentage of Participants who Achieved Technical Success in the Active Drug Group Percentage of Participants who Achieved Procedural Success in the Active Drug Group Number of Participants with Ocular Adverse Events (AEs) and Serious Adverse Events (SAEs) Mean Change From Baseline at 6 and 12 Months in Participants Reported Health-Related Quality of Life as Assessed by National Eye Institute Visual Function Questionnaire (NEIVFQ- 25), SF-36 and FRI | — |
Outcome results
None listed